X4 Pharmaceuticals, IncXFOREarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
X4 Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing novel targeted therapies for rare immunological diseases and oncology indications with high unmet medical needs. It operates primarily across the U.S. and European markets, with a lead pipeline candidate for WHIM syndrome and multiple other preclinical and clinical assets for immune disorders and cancer.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| Bain Capital Life Sciences Fund, L.P. | 9.99% | 16.9M | — | 2024-02-13 |
| Growth Equity Opportunities 18 VGE, LLC | 9.99% | 15.7M | — | 2023-05-26 |
| OrbiMed Advisors LLC | 6.70% | 11.5M | — | 2024-02-14 |
| BlackRock, Inc. | 6.70% | 11.2M | flat | 2024-11-08 |
| The Vanguard Group | 5.00% | 8.4M | flat | 2024-11-12 |
| Acorn Bioventures, L.P. | 4.80% | 8.2M | — | 2024-02-14 |
| Empery Asset Management, LP | 2.65% | 4.5M | — | 2024-01-08 |
| Millennium Management LLC | 1.00% | 1.7M | ▼ -4.20pp | 2024-01-16 |
| Lincoln Park Capital Fund, LLC | 0.95% | 1.6M | — | 2024-02-14 |
Insider Transactions
Net 90d: +$0 · buys $0 / sells $0Range:
Action:
Role:
No transactions match these filters.